Sanofi Consumer Healthcare India Reports Strong Q4 CY25 Results and Announces Final Dividend

Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) reported its Q4 and full-year numbers ended December 31, 2025. The update showed steady gains across key categories. The Board also announced a dividend plan, which kept the stock in focus for finance readers.

For Q4 CY25, net profit rose 50.11% year-on-year to Rs 66.5 crore. Profit was Rs 44.3 crore in the same quarter last year, per a February 25 regulatory filing. Revenue from operations grew 47.04% to Rs 251 crore, from Rs 170.7 crore in Q4 CY24.

The Board of Directors "Recommended a final dividend of Rs. 75/- per equity share having face value of Rs.10/- each for the Financial Year ended 31st December 2025, subject to approval by shareholders of the Company at the ensuing Annual General Meeting (AGM). The Company shall inform in due course the record date / book closure for payment of dividend," said the pharma company in a statement.

At 9:32 AM IST on February 27, 2026, Sanofi Consumer Healthcare India Ltd traded at Rs 4,646.80. On February 26, 2026, the stock rose about 15-16% after strong Q4 FY25 results. Over the last year, it touched Rs 5,894.50 and Rs 3,975.00.

"Sanofi Consumer stock price is bearish on the Daily charts with strong resistance at 4051. A Daily close below support of 3985 could lead to a target of 3712 in the near term," commented A R Ramachandran, part-time SEBI-registered Research Analyst, Tips2trades.

Full-year CY25 sales stood at Rs 878.4 crore, up 21% year-on-year. CY25 profit after tax increased 33% to Rs 240.1 crore. The views shared are from analysts or entities, not Goodreturns.in or Greynium Information Technologies Private Limited. Content is informational, not investment advice, and should be verified with licensed advisors.

Key reported figures are listed below for quick reference by finance readers.

Metric	Period	Value	YoY change
Net profit	Q4 CY25	Rs 66.5 crore	+50.11%
Revenue from operations	Q4 CY25	Rs 251 crore	+47.04%
Sales	Full year 2025	Rs 878.4 crore	+21%
PAT	CY25	Rs 240.1 crore	+33%
Final dividend (recommended)	FY ended 31st December 2025	Rs 75 per equity share	Subject to shareholder approval